证券代码：600079 证券简称：人福医药 编号：临2025-109

Group 1 - The company announced the initiation of a Phase II clinical trial for Yucan Granules aimed at treating diabetic kidney disease with significant albuminuria, which is a multi-center, randomized, double-blind, placebo-controlled study [1] - The trial is registered under the number CTR20253580 and aims to evaluate the efficacy and safety of Yucan Granules, providing a basis for Phase III clinical research [1][2] - Yucan Granules is based on clinical experience from the Department of Nephrology at Shanghai University of Traditional Chinese Medicine and has been used in clinical applications for many years [2] Group 2 - The product is designed to supplement the spleen and kidney, invigorate blood circulation, and promote diuresis, specifically for treating diabetic kidney disease with proteinuria [2] - The total sales of existing similar products, Keluoxin Capsules and Qizhi Yishen Capsules, are projected to be approximately RMB 80 million for the year 2024 [2] - The project has incurred a cumulative research and development investment of approximately RMB 9 million to date [2]